Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 11/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935575 | 1.00 | MAOA (0.56) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL5935590 | 0.89 | PIM1 (0.54) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL7009625 | 0.89 | PIM1 (0.54) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL5935636 | 0.88 | HPGD (0.53) | MAOAMAOBHPGDPIM1PIM2 | |
| SCHEMBL5935593 | 0.82 | MEN1 (0.55) | HPGD | |
| SCHEMBL5935704 | 0.81 | HPGD (0.57) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL6359259 | 0.81 | HPGD (0.57) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL7010573 | 0.81 | HPGD (0.60) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL5935589 | 0.81 | HPGD (0.60) | MAOAMAOBHPGDPTPN1POLB | |
| SCHEMBL7462410 | 0.80 | PIM1 (0.56) | MAOAMAOBHPGDPTPN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958296-B1 | HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | REDDYS LAB LTD DR (IN) | 2003-07-30 | — | — | EP | claimed |
| US-6372750-B2 | COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIZOLIDINE-2,4-DIONE MADE BY CYCLIZATION, CHEMICAL REDUCTION, HYDROLYSIS, AZOLIDINEDIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-16 | — | — | US | claimed |
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S LABORATORIES LIMITED | 2005-02-10 | — | — | US | disclosed |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B2 | MAOA 817/4885MAOB 482/4885HPGD 489/4885 |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | MAOA 920/4885MAOB 532/4885HPGD 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.